利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.017 秒)

    BENZIMIDAZOLE DERIVATIVES AS SELECTIVE ACID PUMP INHIBITORS
    14.
    发明授权
    BENZIMIDAZOLE DERIVATIVES AS SELECTIVE ACID PUMP INHIBITORS 有权
    苯并咪唑选择性酸泵抑制剂

    公开(公告)号：EP2081939B1

    公开(公告)日：2011-06-15

    申请号：EP07825160.0

    申请日：2007-09-17

    申请人： RaQualia Pharma Inc

    发明人： KOIKE, Hiroki ,  MORITA, Mikio

    IPC分类号： C07D491/04 ,  A61K31/4188 ,  A61P1/04 ,  A61P1/08 ,  A61P11/06

    CPC分类号： C07D491/052 ,  C07D491/14

    摘要： Abstract This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R4, A and E are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use, comprising such compounds for the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zolliπger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, cancer, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

    CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS
    15.
    发明授权
    CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS 有权
    苯并二氢吡喃取代的苯并咪唑衍生物作为酸泵拮抗剂

    公开(公告)号：EP1893197B1

    公开(公告)日：2009-09-09

    申请号：EP06765513.4

    申请日：2006-06-02

    申请人： RaQualia Pharma Inc

    发明人： KOIKE, Hiroki, c/o SugiyamaDrugs Co. Ltd. ,  SAKAKIBARA, Sachiko

    IPC分类号： A61K31/4184 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  A61P1/04

    CPC分类号： C07D405/12 ,  C07D405/14

    摘要： This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R1, R2, R3 , R4 , R5 and R6, R7, R8 and R9 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

    TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE
    17.
    发明公开
    TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE 审中-公开

    公开(公告)号：EP4183415A1

    公开(公告)日：2023-05-24

    申请号：EP21842049.5

    申请日：2021-07-16

    申请人： RaQualia Pharma Inc.

    发明人： OHARA Kentaro ,  WATANABE Shuzo ,  HARA Hideaki ,  SHIMAZAWA Masamitsu ,  SUGARU Eiji

    IPC分类号： A61K45/00 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/5377 ,  A61K39/395 ,  A61K48/00 ,  A61P27/02 ,  A61P27/06 ,  G01N33/50

    摘要： The present invention relates to a use of compounds having TRPV4 inhibitory activity or pharmaceutically acceptable salts thereof, or pharmaceutical compositions containing them for the manufacture of a medicament for preventing or treating a retinal disease accompanied with blood flow disorder or cell disorder. It also relates to a method for preventing or treating the disease, wherein the method comprises administering the compounds or the pharmaceutical compositions containing them to humans or animals. The compounds, the pharmaceutically acceptable salts thereof, or the pharmaceutical compositions containing them may be used in combination with one or more second active agents. The present invention relates to a pharmaceutical composition and a kit containing a compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof, which is used for preventing or treating the disease. Furthermore, it relates to a marker for diagnosing a disease for which treatment with the compound is useful, and a screening method for drugs in preventing or treating the disease.

    BENZISOXAZOLE DERIVATIVE SALT
    20.
    发明公开
    BENZISOXAZOLE DERIVATIVE SALT 审中-公开
    苯并恶唑衍生物盐

    公开(公告)号：EP3145926A1

    公开(公告)日：2017-03-29

    申请号：EP15796887.6

    申请日：2015-05-20

    申请人： RaQualia Pharma Inc

    发明人： NUMATA, Toyoharu ,  SUDO, Masaki ,  SUN, Xufeng

    IPC分类号： C07D413/14 ,  A61K31/454 ,  A61P1/04 ,  A61P1/10 ,  A61P1/14 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P11/16 ,  A61P25/00 ,  A61P25/06 ,  A61P25/28 ,  A61P43/00

    CPC分类号： C07D413/14 ,  A61K31/454

    摘要： Salts of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid are disclosed. More particularly, salt forms (HCl-salt, HBr-salt, p-toluenesulfonate salt and ethanedisulfonate salt) are disclosed. Furthermore, processes for the preparation of such salt forms, compositions containing such salt forms, and uses of such salt forms are disclosed. A method of treating disease conditions mediated by 5-HT4 receptor activity includes administering an effective amount of such salt forms to an animal, including a human, in need of such treatment.

    摘要翻译： 4 - {[4-（2,2,2-三氟乙氧基）-1,2-苯并异恶唑-3-基]氧基}甲基）哌啶-1-基]甲基}四氢-2H-吡喃 -4-羧酸。 更具体地说，公开了盐形式（盐酸盐，HBr盐，对甲苯磺酸盐和乙二磺酸盐）。 此外，还公开了制备这种盐形式的方法，含有这种盐形式的组合物以及这些盐形式的用途。 治疗由5-HT 4受体活性介导的疾病状况的方法包括将有效量的这种盐形式给予需要这种治疗的动物，包括人。